Eurofins CDMO vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison
Side-by-side comparison of Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates; Eurofins CDMO does not appear in EudraGMDP.
- Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) qualify as Cell Therapy manufacturers; Merck KGaA / MilliporeSigma (CDMO) carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Eurofins CDMO vs Merck KGaA / MilliporeSigma (CDMO)
Which has the stronger FDA inspection record, Eurofins CDMO or Merck KGaA / MilliporeSigma (CDMO)?
Both Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Eurofins CDMO has 4 FDA inspections on record; Merck KGaA / MilliporeSigma (CDMO) has 2.
How do Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?
Eurofins CDMO holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Eurofins CDMO or Merck KGaA / MilliporeSigma (CDMO)?
Eurofins CDMO is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Eurofins CDMO or Merck KGaA / MilliporeSigma (CDMO)?
Both Eurofins CDMO and Merck KGaA / MilliporeSigma (CDMO) are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Eurofins CDMO carries a Signal Score of 82/100 and Merck KGaA / MilliporeSigma (CDMO) carries 82/100 — essentially tied for Merck KGaA / MilliporeSigma (CDMO). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →